Key facts
- Immunofoco Biotechnology’s last known valuation is $298.1M (Feb 2026).
- It has raised $138.8M; the latest was IPO in Feb 2026.
- Notable investors include ZhenFund, Green Pine Capital Partners, Shenzhen Nanshan Strategic Emerging Industry Investment, Orinno Capital, Beijing Delian Yuntong Investment Management Company — 27 tracked in total.
- Status: In IPO Registration.
Investors
27+- ·The complete investor list — 27 names
- ·Watchlist + deal alerts for Immunofoco Biotechnology
- ·The full record, as it builds
Funding rounds
No funding rounds for Immunofoco Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immunofoco Biotechnology
Developer and manufacturer of CAR-T cell therapies and innovative treatment platforms designed for solid tumors and hematological cancers. The company provides clinical-stage drug candidates and off-the-shelf solutions, enabling oncology patients and healthcare providers with enhanced therapeutic options, improved survival outcomes, and more accessible cellular immunotherapy.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2020
- Employees
- 105
- Website
- immunofoco.com/
- Ownership
- In IPO Registration
Immunofoco Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immunofoco Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immunofoco Biotechnology in its N-PORT filings yet. We sweep new filings monthly.